October 1, 2014
XOMA announced the launch of a U.S. clinical trial to investigate the safety and efficacy of gevokizumab for the treatment of patients with Behçet’s disease uveitis, according to a press release issued by the company.
The EYEGUARD-US trial will comprise up to 28 patients administered the monoclonal antibody, gevokizumab, in an open-label design. Patients who respond to gevokizumab by day 28 will be randomly assigned in a 1:1, double-masked fashion to either gevokizumab 60 mg or placebo, administered subcutaneously once monthly, according to the press release. The study’s primary endpoint is the time to first ocular exacerbation following randomization.